•  
  •  
  •  
  •  

2025-06-24 02:59:01

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Enviro Infra Engineers Ltd secures new projects worth Rs. 306.30 crores
  • Globe Civil Projects raises Rs 35.70 crores from Anchor Investors
  • AVG Logistics Ltd announces inauguration of Electric Vehicles in TATA Steel
  • JSW Energy Limited settles debt of KSK Water Infrastructures Pvt Ltd
  • Adani Electricity Mumbai Ltd concludes USD 49.5 Mn Open Market Repurchase of its Senior Secured Notes

Keywords Selected:  USFDA

Stock Report

  • Unichem Laboratories Ltd receives Form 483 from USFDA with 3 observations for Roha API facility
  • Granules India Ltd receives Form 483 with 1 observation from USFDA for Bonthapally API unit 1
  • NATCO Pharma Ltd announces conclusion of USFDA inspection at Pharma Division, Kothur
  • Closure of USFDA inspection at Zydus' oncology injectable plant at Ahmedabad
  • Alembic Pharmaceuticals Ltd receives EIR from USFDA for API-III facility at Karakhadi
  • U.S. FDA inspection at Glenmark Pharma's Facility at Monroe, North Carolina, USA
  • USFDA conducts GCP inspection at Syngene International Ltd's facility at Semicon Park, Bengaluru
  • Sun Pharma gets 8 observations from USFDA for Halol facility
  • Syngene International Ltd updates on USFDA inspection at Biocon Park, SEZ, Bengaluru
  • USFDA inspection at the API manufacturing plant located in Mekaguda, Hyderabad
  • Zydus receives EIR for the API manufacturing facility at Ankleshwar
  • Zydus receives EIR for the API manufacturing facility at Dabhasa
  • OneSource's flagship drug-device combination facility in Bangalore maintains its USFDA compliance status
  • Lupin receives tentative approval from U.S. FDA for Oxcarbazepine ER Tablets
  • Gland Pharma Receives Approval for Angiotensin II Acetate Injection
  • Piramal Pharma Ltd completes USFDA inspection of Aurora facility with Zero Form-483 observations
  • Zydus receives tentative approval from USFDA for Rifaximin Tablets, 550 mg
  • USFDA classifies Medgel Pvt Ltd's facility as VAI
  • Zydus receives final approval from USFDA for Isotretinoin Capsules USP, 10 mg 20 mg, 25 mg, 30 mg, 35 mg and 40 mg
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Amlodipine and Atorvastatin Tablets USP
  • Indoco Remedies receives final approval from the USFDA for Allopurinol Tablets USP 200 mg
  • USFDA completes GMP inspection at Dr. Reddy's Laboratories Ltd's API Middleburgh facility
  • Sun Pharma Announces FDA Approval of Next Generation BLU-U® Blue Light Photodynamic Therapy Illuminator for Actinic Keratosis
  • Lupin receives approval from U.S. FDA for Rivaroxaban Tablets USP, 10 mg, 15 mg, and 20 mg

Latest Post

  • Enviro Infra Engineers Ltd secures new projects worth Rs. 306.30 crores
  • Globe Civil Projects raises Rs 35.70 crores from Anchor Investors
  • AVG Logistics Ltd announces inauguration of Electric Vehicles in TATA Steel
  • JSW Energy Limited settles debt of KSK Water Infrastructures Pvt Ltd
  • Adani Electricity Mumbai Ltd concludes USD 49.5 Mn Open Market Repurchase of its Senior Secured Notes


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024